EFFICACY OF DOUBLE DOSE PHOTODYNAMIC THERAPY FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA

Ji Hwan Lee, Christopher Seungkyu Lee, Sungchul Lee

Research output: Contribution to journalArticle

Abstract

PURPOSE: To evaluate the efficacy of photodynamic therapy using a double dose of verteporfin for patients with circumscribed choroidal hemangioma. METHODS: This retrospective comparative case series evaluated data from 10 patients who were treated using double dose photodynamic therapy (12 mg/m) and seven patients who were treated using the standard dose (6 mg/m). A laser was applied with a radiant exposure of 50 J/cm. The ophthalmologic examinations were performed at baseline and 1 year after the treatment and included best-corrected visual acuity, slit-lamp biomicroscopy, fundus examination, spectral domain optical coherence tomography, and B-scan ultrasonography. RESULTS: The mean age in the double dose group was 51.60 years, compared with 50.57 years in the standard-dose group. The only significant difference between the two groups' baseline characteristics was observed in their initial tumor heights. Foveal center thickness, subretinal fluid, and subfoveal choroidal thickness decreased significantly at 1 year after treatment in both groups. Tumor height and the greatest linear dimension of the tumor's base only decreased significantly in the double dose group (P = 0.031). Both groups did not experience significant visual improvements. CONCLUSION: Double dose photodynamic therapy was effective and safe for treating circumscribed choroidal hemangioma and provided better tumor regression with similar resorption of subretinal fluid, compared with standard-dose photodynamic therapy.

Original languageEnglish
Pages (from-to)392-397
Number of pages6
JournalRetina (Philadelphia, Pa.)
Volume39
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

Photochemotherapy
Hemangioma
Subretinal Fluid
Neoplasms
Optical Coherence Tomography
Visual Acuity
Ultrasonography
Lasers
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Lee, Ji Hwan ; Lee, Christopher Seungkyu ; Lee, Sungchul. / EFFICACY OF DOUBLE DOSE PHOTODYNAMIC THERAPY FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA. In: Retina (Philadelphia, Pa.). 2019 ; Vol. 39, No. 2. pp. 392-397.
@article{e75988ec9fbb4068860023bc1aa37136,
title = "EFFICACY OF DOUBLE DOSE PHOTODYNAMIC THERAPY FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA",
abstract = "PURPOSE: To evaluate the efficacy of photodynamic therapy using a double dose of verteporfin for patients with circumscribed choroidal hemangioma. METHODS: This retrospective comparative case series evaluated data from 10 patients who were treated using double dose photodynamic therapy (12 mg/m) and seven patients who were treated using the standard dose (6 mg/m). A laser was applied with a radiant exposure of 50 J/cm. The ophthalmologic examinations were performed at baseline and 1 year after the treatment and included best-corrected visual acuity, slit-lamp biomicroscopy, fundus examination, spectral domain optical coherence tomography, and B-scan ultrasonography. RESULTS: The mean age in the double dose group was 51.60 years, compared with 50.57 years in the standard-dose group. The only significant difference between the two groups' baseline characteristics was observed in their initial tumor heights. Foveal center thickness, subretinal fluid, and subfoveal choroidal thickness decreased significantly at 1 year after treatment in both groups. Tumor height and the greatest linear dimension of the tumor's base only decreased significantly in the double dose group (P = 0.031). Both groups did not experience significant visual improvements. CONCLUSION: Double dose photodynamic therapy was effective and safe for treating circumscribed choroidal hemangioma and provided better tumor regression with similar resorption of subretinal fluid, compared with standard-dose photodynamic therapy.",
author = "Lee, {Ji Hwan} and Lee, {Christopher Seungkyu} and Sungchul Lee",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/IAE.0000000000001967",
language = "English",
volume = "39",
pages = "392--397",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

EFFICACY OF DOUBLE DOSE PHOTODYNAMIC THERAPY FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA. / Lee, Ji Hwan; Lee, Christopher Seungkyu; Lee, Sungchul.

In: Retina (Philadelphia, Pa.), Vol. 39, No. 2, 01.02.2019, p. 392-397.

Research output: Contribution to journalArticle

TY - JOUR

T1 - EFFICACY OF DOUBLE DOSE PHOTODYNAMIC THERAPY FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA

AU - Lee, Ji Hwan

AU - Lee, Christopher Seungkyu

AU - Lee, Sungchul

PY - 2019/2/1

Y1 - 2019/2/1

N2 - PURPOSE: To evaluate the efficacy of photodynamic therapy using a double dose of verteporfin for patients with circumscribed choroidal hemangioma. METHODS: This retrospective comparative case series evaluated data from 10 patients who were treated using double dose photodynamic therapy (12 mg/m) and seven patients who were treated using the standard dose (6 mg/m). A laser was applied with a radiant exposure of 50 J/cm. The ophthalmologic examinations were performed at baseline and 1 year after the treatment and included best-corrected visual acuity, slit-lamp biomicroscopy, fundus examination, spectral domain optical coherence tomography, and B-scan ultrasonography. RESULTS: The mean age in the double dose group was 51.60 years, compared with 50.57 years in the standard-dose group. The only significant difference between the two groups' baseline characteristics was observed in their initial tumor heights. Foveal center thickness, subretinal fluid, and subfoveal choroidal thickness decreased significantly at 1 year after treatment in both groups. Tumor height and the greatest linear dimension of the tumor's base only decreased significantly in the double dose group (P = 0.031). Both groups did not experience significant visual improvements. CONCLUSION: Double dose photodynamic therapy was effective and safe for treating circumscribed choroidal hemangioma and provided better tumor regression with similar resorption of subretinal fluid, compared with standard-dose photodynamic therapy.

AB - PURPOSE: To evaluate the efficacy of photodynamic therapy using a double dose of verteporfin for patients with circumscribed choroidal hemangioma. METHODS: This retrospective comparative case series evaluated data from 10 patients who were treated using double dose photodynamic therapy (12 mg/m) and seven patients who were treated using the standard dose (6 mg/m). A laser was applied with a radiant exposure of 50 J/cm. The ophthalmologic examinations were performed at baseline and 1 year after the treatment and included best-corrected visual acuity, slit-lamp biomicroscopy, fundus examination, spectral domain optical coherence tomography, and B-scan ultrasonography. RESULTS: The mean age in the double dose group was 51.60 years, compared with 50.57 years in the standard-dose group. The only significant difference between the two groups' baseline characteristics was observed in their initial tumor heights. Foveal center thickness, subretinal fluid, and subfoveal choroidal thickness decreased significantly at 1 year after treatment in both groups. Tumor height and the greatest linear dimension of the tumor's base only decreased significantly in the double dose group (P = 0.031). Both groups did not experience significant visual improvements. CONCLUSION: Double dose photodynamic therapy was effective and safe for treating circumscribed choroidal hemangioma and provided better tumor regression with similar resorption of subretinal fluid, compared with standard-dose photodynamic therapy.

UR - http://www.scopus.com/inward/record.url?scp=85060544963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060544963&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000001967

DO - 10.1097/IAE.0000000000001967

M3 - Article

VL - 39

SP - 392

EP - 397

JO - Retina

JF - Retina

SN - 0275-004X

IS - 2

ER -